The study also analyzed how drugmakers have implemented processes that comply with the Food and Drug Administration’s draft guidance issued in 2022 to improve diversity.
Boehringer Ingelheim, Walgreens partner to diversify clinical trials
Boehringer Ingelheim and Walgreens are seeking out people who are overweight, living with obesity or have type 2 diabetes — specifically Black and Hispanic patient populations.
Eli Lilly’s GLP-1 drug achieves endpoints in Phase 3 sleep apnea trials
The sleep apnea results point to the continued clinical promise of GLP-1 drugs for treating other medical conditions and disease states beyond type 2 diabetes and obesity.
After Phase 3 readout, Ionis set on launching FCS agent this year
VX-548, designed as an alternative to opioids in treating acute pain, posted mixed trial results. Some analysts are questioning the commercial viability of Vertex’s drug.
Sagimet’s liver drug impresses in year-long NASH trial
The pill from Sagimet Biosciences led to a statistically significant treatment effect in patients with NASH and moderate-to-severe liver fibrosis at the 52-week mark, data show.
Ionis’ long-term HAE drug lowered attack rates, topline Phase 3 results show
The results from Ionis suggest the drug, donidalorsen, led to a statistically significant reduction in the rate of HAE attacks in patients treated every four or eight weeks.
GSK, the Tigerlily Foundation want to diversify clinical trials